Planet 13 Holdings (PLNH) Net Income towards Common Stockholders (2021 - 2026)
Planet 13 Holdings (PLNH) reported Net Income towards Common Stockholders of -$8.1 million for Q1 2026, down 295.46% year-over-year from $4.1 million in Q1 2025, and down 232.19% quarter-over-quarter from $6.1 million in Q4 2025.
Planet 13 Holdings (PLNH) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Planet 13 Holdings (PLNH) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$8.1 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$8.1 million, down 295.46% year-over-year; the trailing twelve-month figure through Mar 2026 was -$59.2 million (down 34.7% YoY), and the FY2025 annual result was -$53.2 million, down 11.26% from the prior year.
- Net Income towards Common Stockholders slipped to -$8.1 million in Q1 2026 per PLNH's latest filing, from $6.1 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $6.1 million in Q4 2025 and troughed at -$46.3 million in Q3 2023.
- A 5-year average of -$14.2 million and a median of -$8.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders sank 2131.73% in 2022, then jumped 123.16% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$42.1 million in 2022, then jumped by 66.13% to -$14.3 million in 2023, then sank by 85.43% to -$26.4 million in 2024, then jumped by 123.16% to $6.1 million in 2025, then slumped by 232.19% to -$8.1 million in 2026.
- Business Quant data shows PLNH's Net Income towards Common Stockholders at -$8.1 million in Q1 2026, $6.1 million in Q4 2025, and -$44.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 1.99 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Planet 13 Holdings | - | - | 9.41 Mn | -8.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.10 Mn |
| Dec 31, 2025 | 6.12 Mn |
| Sep 30, 2025 | -43.96 Mn |
| Jun 30, 2025 | -13.30 Mn |
| Mar 31, 2025 | -2.05 Mn |
| Dec 31, 2024 | -26.44 Mn |
| Sep 30, 2024 | -7.41 Mn |
| Jun 30, 2024 | -8.07 Mn |
| Mar 31, 2024 | -5.87 Mn |
| Dec 31, 2023 | -14.26 Mn |
| Sep 30, 2023 | -46.25 Mn |
| Jun 30, 2023 | -4.62 Mn |
| Mar 31, 2023 | -8.48 Mn |
| Dec 31, 2022 | -42.09 Mn |
| Sep 30, 2022 | -6.32 Mn |
| Jun 30, 2022 | -7.07 Mn |
| Mar 31, 2022 | -4.06 Mn |
| Dec 31, 2021 | -27.41 Mn |
| Sep 30, 2021 | 4.05 Mn |
| Jun 30, 2021 | 347,962.00 |